Pharmacokinetic and pharmacodynamic considerations in antimalarial dose optimization

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 12, 2013, Pages 5792-5807

  White, Nicholas J ^a,b  

^a MAHIDOL UNIVERSITY   (Thailand)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOQUINOLINE DERIVATIVE; ANTIMALARIAL AGENT; ARTEETHER; ARTEMETHER PLUS BENFLUMETOL; ARTEMISININ DERIVATIVE; ARTEROLANE; ARTESUNATE; ATOVAQUONE; ATOVAQUONE PLUS PROGUANIL; CHLOROQUINE; CHLOROQUINE PLUS PRIMAQUINE; CHLORPROGUANIL PLUS DAPSONE; CINCHONA ALKALOID; CINCHONIDINE; CINCHONINE; DIHYDROARTEMISININ PLUS PIPERAQUINE; HALOFANTRINE; KAE 609; MEFLOQUINE; MEPACRINE; OZ 439; PRIMAQUINE; PYRIMETHAMINE PLUS SULFADOXINE; QUINIDINE; QUININE; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ANTIMALARIAL ACTIVITY; ANTIMALARIAL DRUG SUSCEPTIBILITY; AREA UNDER THE CURVE; BIOMASS; BRAIN MALARIA; CALIBRATION; CELL ADHESION; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DOSE CALCULATION; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG EXPOSURE; DRUG HALF LIFE; DRUG MEGADOSE; DRUG METABOLISM; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; GROUPS BY AGE; GROWTH INHIBITION; HOST RESISTANCE; HUMAN; HYDROPHOBICITY; HYPOTENSION; IN VITRO STUDY; IN VIVO STUDY; INNATE IMMUNITY; LIPOPHILICITY; LOADING DRUG DOSE; LOW DRUG DOSE; MALARIA FALCIPARUM; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MORTALITY; NONHUMAN; OPTIMAL DRUG DOSE; PARASITE CLEARANCE; PARASITE LOAD; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLASMODIUM VIVAX MALARIA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; RECURRENT DISEASE; REVIEW; SINGLE DRUG DOSE; TREATMENT DURATION; TREATMENT RESPONSE; ADULT; CHILD; CLINICAL TRIAL (TOPIC); DRUG ADMINISTRATION; DRUG EFFECTS; DRUG MONITORING; DRUG RESISTANCE; FEMALE; GROWTH, DEVELOPMENT AND AGING; MALARIA, FALCIPARUM; MICROBIAL SENSITIVITY TEST; PARASITOLOGY; PLASMODIUM FALCIPARUM; PREGNANCY; STATISTICAL MODEL;

ADULT; ANTIMALARIALS; CHILD; CLINICAL TRIALS AS TOPIC; DRUG ADMINISTRATION SCHEDULE; DRUG DOSAGE CALCULATIONS; DRUG MONITORING; DRUG RESISTANCE; FEMALE; HUMANS; MALARIA, FALCIPARUM; MICROBIAL SENSITIVITY TESTS; MODELS, STATISTICAL; PLASMODIUM FALCIPARUM; PREGNANCY;

EID: 84887416507     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00287-13     Document Type: Review

References (81)

1. World Health Organization. 2010. Guidelines for the treatment of malaria. World Health Organization, Geneva, Switzerland.
2. Ashley EA, Pinoges L, Turyakira E, Dorsey G, Checchi F, Bukirwa H, van den Broek I, Zongo I, Urruta PP, van Herp M, Balkan S, Taylor WR, Olliaro P, Guthmann JP. 2008. Different methodological approaches to the assessment of in vivo efficacy of three artemisinin-based combination antimalarial treatments for the treatment of uncomplicated falciparum malaria in African children. Malar. J. 7:154. doi:10.1186/1475-2875-7-154.
3. World Health Organization. 2003. Assessment and monitoring of antimalarial drug efficacy for the treatment of uncomplicated falciparum malaria. World Health Organization, Geneva, Switzerland.
4. Barnes KI, Little F, Smith PJ, Evans A, Watkins WM, White NJ. 2006. Sulfadoxine-pyrimethamine pharmacokinetics in malaria: pediatric dosing implications. Clin. Pharmacol. Ther. 80:582-596.
5. Baird JK, Hoffman SL. 2004. Primaquine therapy for malaria. Clin. Infect. Dis. 39:1336-1345.
6. de Souza JM, Sheth UK, Wernsdorfer WH, Trigg PI, Doberstyn EB. 1987. A phase II/III double-blind, dose-finding clinical trial of a combination of mefloquine, sulfadoxine, and pyrimethamine (Fansimef) in falciparum malaria. Bull. World Health Organ. 65:357-361.
7. Harinasuta T, Bunnag D, Vanijanond S, Charoenlarp P, Suntharasamai P, Chitamas S, Sheth UK, Wernsdorfer WH. 1987. Mefloquine, sulfadoxine, and pyrimethamine in the treatment of symptomatic falciparum malaria: a double-blind trial for determining the most effective dose. Bull. World Health Organ. 65:363-367.
8. Simpson JA, Watkins ER, Price RN, Aarons L, Kyle DE, White NJ. 2000. Mefloquine pharmacokinetic-pharmacodynamic models: implications for dosing and resistance. Antimicrob. Agents Chemother. 44:3414-3424.
9. White NJ, van Vugt M, Ezzet F. 1999. Clinical pharmacokinetics and pharmacodynamics of artemether-lumefantrine. Clin. Pharmacokinet. 37:105-125.
10. Wilairatana P, Krudsood S, Chalermrut K, Pengruksa C, Srivilairit S, Silachamroon U, Treeprasertsuk S, Looareesuwan S. 2002. An open randomized clinical trial of Artecom vs artesunate-mefloquine in the treatment of acute uncomplicatedfalciparum malaria in Thailand. Southeast Asian J. Trop. Med. Public Health 33:519-524.
11. Tarning J, Zongo I, Somé FA, Rouamba N, Parikh S, Rosenthal PJ, Hanpithakpong W, Jongrak N, Day NP, White NJ, Nosten F, Ouedraogo JB, Lindegardh N. 2012. Population pharmacokinetics and pharmacodynamics of piperaquine in children with uncomplicated falciparum malaria. Clin. Pharmacol. Ther. 91:497-505.
12. White NJ, Looareesuwan S, Warrell DA, Warrell MJ, Chanthavanich P, Bunnag D, Harinasuta T. 1983. Quinine loading dose in cerebral malaria. Am. J. Trop. Med. Hyg. 32:1-5.
13. Nealon C, Dzeing A, Müller-Römer U, Planche T, Sinou V, Kombila M, Kremsner PG, Parzy D, Krishna S. 2002. Intramuscular bioavailability and clinical efficacy of artesunate in Gabonese children with severe malaria. Antimicrob. Agents Chemother. 46:3933-3939.
14. Hien TT, Arnold K, Vinh H, Cuong BM, Phu NH, Chau TT, Hoa NT, Chuong LV, Mai NT, Vinh NN, Trang TTM. 1992. Comparison of artemisinin suppositories with intravenous artesunate and intravenous quinine in the treatment of cerebral malaria. Trans. R. Soc. Trop. Med. Hyg. 86:582-583.
15. Dondorp A, Nosten F, Stepniewska K, Day N, White NJ; South East Asian Quinine Artesunate Malaria Trial (SEAQUAMAT) group. 2005. Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial. Lancet 366:717-725.
16. Dondorp AM, Fanello CE, Hendriksen ICE, Gomes E, Seni A, Chhaganlal KD, Bojang K, Olaosebikan R, Anunobi N, Maitland K, Kivaya E, Agbenyega T, Nguah SB, Evans J, Gesase S, Kahabuka C, Mtove G, Nadjm B, Deen J, Mwanga-Amumpaire J, Nansumba M, Karema C, Umulisa N, Uwimana A, Mokuolu OA, Adedoyin TO, Johnson WBR, Tshefu AK, Onyamboko MA, Sakulthaew T, Pan-Ngum W, Silamut K, Stepniewska K, Woodrow C, Bethell D, Wills B, Oneko M, Peto T, von Seidlein L, Day NPJ, White NJ, for the AQUAMAT group. 2010. Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial. Lancet 376:1647-1657.
17. Hendriksen IC, Mtove G, Kent A, Gesase S, Reyburn H, Lemnge MM, Lindegardh N, Day NP, von Seidlein L, White NJ, Dondorp AM, Tarning J. 2013. Population pharmacokinetics of intramuscular artesunate in African children with severe malaria: implications for a practical dosing regimen. Clin. Pharmacol. Ther. 93:443-450.
18. Ding XC, Ubben D, Wells TN. 2012. A framework for assessing the risk of resistance for anti-malarials in development. Malar. J. 11:292. doi:10 .1186/1475-2875-11-292.
19. Sanz LM, Crespo B, De-Cózar C, Ding XC, Llergo JL, Burrows JN, García-Bustos JF, Gamo FJ. 2012. P. falciparum in vitro killing rates allow to discriminate between different antimalarial mode-of-action. PLoS One 7:e30949. doi:10.1371/journal.pone.0030949.
20. Duparc S, Lanza C, Ubben D, Borghini-Fuhrer I, Kellam L. 2012. Optimal dose finding for novel antimalarial combination therapy. Trop. Med. Int. Health 17:409-413.
21. McCarthy JS, Sekuloski S, Griffin PM, Elliott S, Douglas N, Peatey C, Rockett R, O'Rourke P, Marquart L, Hermsen C, Duparc S, Möhrle J, Trenholme KR, Humberstone AJ. 2011. A pilot randomised trial of induced blood-stage Plasmodium falciparum infections in healthy volunteers for testing efficacy of newantimalarial drugs. PLoS One 6:e21914. doi:10.1371/journal.pone.0021914.
22. Barnes KI, Watkins WM, White NJ. 2008. Antimalarial dosing regimens and drug resistance. Trends Parasitol. 24:127-134.
23. White NJ. 2002. The assessment of antimalarial drug efficacy. Trends Parasitol. 18:458-464.
24. Simpson JA, Jamsen KM, Price RN, White NJ, Lindegardh N, Tarning J, Duffull SB. 2009. Towards optimal design of anti-malarial pharmacokinetic studies. Malar. J. 8:189. doi:10.1186/1475-2875-8-189.
25. Ashley EA, Stepniewska K, Lindegardh N, Annerberg A, Tarning J, McGready R, Phaiphun L, Singhasivanon P, White NJ, Nosten F. 2010. Comparison of plasma, venous and capillary blood levels of piperaquine in patients with uncomplicated falciparum malaria. Eur. J. Clin. Pharmacol. 66:705-712.
26. Rombo L, Kihamia CM, Mahikwano LF, Ericsson O, Sjöqvist F. 1986. Concentrations of chloroquine and desethylchloroquine in capillary blood dried on filter paper during and after treatment of Tanzanian children infected with Plasmodium falciparum. Trop. Med. Parasitol. 37:237-240.
27. World Wide Antimalarial Resistance Network. http://www.wwarn.org. Accessed 12 September 2012.
28. World Health Organization. 2011. Methods and techniques for assessing exposure to antimalarial drugs in clinical field studies. World Health Organization, Geneva, Switzerland.
29. White NJ. 2013. Primaquine to prevent transmission of falciparum malaria. Lancet Infect. Dis. 13:175-181.
30. ter Kuile F, White NJ, Holloway P, Pasvol G, Krishna S. 1993. Plasmodium falciparum: in vitro studies of the pharmacodynamic properties of drugs used for the treatment of severe malaria. Exp. Parasitol. 76:86-95.
31. Udomsangpetch R, Pipitaporn B, Krishna S, Angus B, Pukrittayakamee S, Bates I, Suputtamongkol Y, Kyle DE, White NJ. 1996. Antimalarial drugs reduce cytoadherence and rosetting of Plasmodium falciparum. J. Infect. Dis. 173:691-698.
32. White NJ. 1997. Assessment of the pharmacodynamic properties of antimalarial drugs in vivo. Antimicrob. Agents Chemother. 41:1413-1422.
33. White NJ. 2011. The parasite clearance curve. Malar. J. 10:278. doi:10 .1186/1475-2875-10-278.
34. Flegg JA, Guerin PJ, White NJ, Stepniewska K. 2011. Standardizing the measurement of parasite clearance in falciparum malaria: the parasite clearance estimator. Malar. J. 10:339. doi:10.1186/1475-2875-10-339.
35. Zaloumis S, Humberstone A, Charman SA, Price RN, Moehrle J, Gamo- Benito J, McCaw J, Jamsen KM, Smith K, Simpson JA. 2012. Assessing the utility of an anti-malarial pharmacokinetic-pharmacodynamic model for aiding drug clinical development. Malar. J. 11:303. doi:10.1186/1475-2875-11-303.
36. Jiménez-Díaz MB, Mulet T, Viera S, Gómez V, Garuti H, Ibánez J, Alvarez-Doval A, Shultz LD, Martínez A, Gargallo-Viola D, Angulo- Barturen I. 2009. Improved murine model of malaria using Plasmodium falciparum competent strains and non-myelodepleted NOD-scid IL2R gamma null mice engrafted with human erythrocytes. Antimicrob. Agents Chemother. 53:4533-4536.
37. Shannon JA, Earle DP, Brodie BB, Taggart JV, Berliner RW. 1944. The pharmacological basis for the rational use of atabrine in the treatment of malaria. J. Pharm. Exp. Ther. 81:307-330.
38. Shannon JA, Earle DP, Berliner RW, Taggart JV. 1948. Studies on the chemotherapy of the human malarias. l. Method for the quantitative assay of suppressive antimalarial action in vivax malaria. J. Clin. Invest. 27(Pt1): 66-74.
39. Earle DP, Berliner RW, Taggart JV, Welch WJ, Zubrod CG, Wise NB, Chalmers TC, Greif RL, Shannon JA. 1948. Studies on the chemotherapy of the human malarias. ll. Method for the quantitative assay of suppressive antimalarial action in falciparum malaria. J. Clin. Invest. 27(Pt1):75-79.
40. Simpson JA, Hughes D, Manyando C, Bojang K, Aarons L, Winstanley P, Edwards G, Watkins WA, Ward S. 2006. Population pharmacokinetic and pharmacodynamic modelling of the antimalarial chemotherapy chlorproguanil/ dapsone. Br. J. Clin. Pharmacol. 61:289-300.
41. Hoshen MB, Stein WD, Ginsburg HD. 2001. Pharmacokineticpharmacodynamic modelling of the antimalarial activity of mefloquine. Parasitology 123:337-346.
42. Pukrittayakamee S, Wanwimolruk S, Stepniewska K, Jantra A, Huyakorn S, Looareesuwan S, White NJ. 2003. Quinine pharmacokinetic- pharmacodynamic relationships in uncomplicated falciparum malaria. Antimicrob. Agents Chemother. 47:3458-3463.
43. Svensson US, Alin H, Karlsson MO, Bergqvist Y, Ashton M. 2002. Population pharmacokinetic and pharmacodynamic modelling of artemisinin and mefloquine enantiomers in patients with falciparum malaria. Eur. J. Clin. Pharmacol. 58:339-351.
44. Djimdé AA, Doumbo OK, Traore O, Guindo AB, Kayentao K, Diourte Y, Niare-Doumbo S, Coulibaly D, Kone AK, Cissoko Y, Tekete M, Fofana B, Dicko A, Diallo DA, Wellems TE, Kwiatkowski D, Plowe CV. 2003. Clearance of drug-resistant parasites as a model for protective immunity in Plasmodium falciparum malaria. Am. J. Trop. Med. Hyg. 69: 558-563.
45. Stepniewska K, White NJ. 2008. The pharmacokinetic determinants of the window of selection for antimalarial drug resistance. Antimicrob. Agents Chemother. 52:1589-1596.
46. White NJ, Pongtavornpinyo W, Maude RJ, Saralamba S, Aguas R, Stepniewska K, Lee SJ, Dondorp AM, White LJ, Day NP. 2009. Hyperparasitaemia and low dosing are an important source of anti-malarial drug resistance. Malar. J. 8:253. doi:10.1186/1475-2875-8-253.
47. Day NPJ, Diep PT, Ly PT, Sinh DX, Loc PP, Chuong LV, Chau TTH, Mai NTH, Bethell DB, Phu NH, Hien TT, White NJ. 1996. Clearance kinetics of parasites and pigment-containing leukocytes in severe malaria. Blood 88:4694-4700.
48. Teuscher F, Gatton ML, Chen N, Peters J, Kyle DE, Cheng Q. 2010. Artemisinin-induced dormancy in Plasmodium falciparum: duration, recovery rates, and implications in treatment failure. J. Infect. Dis. 202: 1362-1368.
49. White NJ, Stepniewska K, Barnes K, Price RN, Simpson J. 2008. Simplified antimalarial therapeutic monitoring: using the Day 7 drug level? Trends Parasitol. 24:159-163.
50. White NJ. 2004. Antimalarial drug resistance. J. Clin. Invest. 113:1084-1092.
51. Winter K, Hastings IM. 2011. Development, evaluation, and application of an in silico model for antimalarial drug treatment and failure. Antimicrob. Agents Chemother. 55:3380-3392.
52. Bergstrand M, Nosten F, Lwin KM, Karlsson M, White NJ, Tarning J. Characterisation of an in vivo concentration-effect relationship for piperaquine in malaria chemoprevention and prediction of therapeutic responses in different patient groups. Sci. Trans. Med., in press.
53. Bell DJ, Nyirongo SK, Mukaka M, Molyneux ME, Winstanley PA, Ward SA. 2011. Population pharmacokinetics of sulfadoxine and pyrimethamine in Malawian children with malaria. Clin. Pharmacol. Ther. 89:268-275.
54. Hietala SF, Martensson A, Ngasala B, Dahlström S, Lindegardh N, Annerberg A, Premji Z, Färnert A, Gil P, Björkman A, Ashton M. 2010. Population pharmacokinetics and pharmacodynamics of artemether and lumefantrine during combination treatment in children with uncomplicated falciparum malaria in Tanzania. Antimicrob. Agents Chemother. 54:4780-4788.
55. Price RN, Hasugian AR, Ratcliff A, Siswantoro H, Purba HL, Kenangalem E, Lindegardh N, Penttinen P, Laihad F, Ebsworth EP, Anstey NM, Tjitra E. 2007. Clinical and pharmacological determinants of the therapeutic response to dihydroartemisinin-piperaquine for drugresistant malaria. Antimicrob. Agents Chemother. 51:4090-4097.
56. Price RN, Uhlemann AC, van Vugt M, Brockman A, Hutagalung R, Nair S, Nash D, Singhasivanon P, Anderson TJ, Krishna S, White NJ, Nosten F. 2006. Molecular and pharmacological determinants of the therapeutic response to artemether-lumefantrine in multidrug-resistant Plasmodium falciparum malaria. Clin. Infect. Dis. 42:1570-1577.
57. Pukrittayakamee S, Imwong M, Chotivanich K, Singhasivanon P, Day NP, White NJ. 2010. A comparison of two short-course primaquine regimens for the treatment and radical cure of Plasmodium vivax malaria in Thailand. Am. J. Trop. Med. Hyg. 82:542-547.
58. White NJ, Qiao LG, Qi G, Luzzatto L. 2012. Rationale for recommending a lower dose of primaquine as a Plasmodium falciparum gametocytocide in populations where G6PD deficiency is common. Malar. J. 11:418. doi:10.1186/1475-2875-11-418.
59. Stepniewska K, White NJ. 2006. Some considerations in the design and interpretation of antimalarial drug trials in uncomplicated falciparum malaria. Malar. J. 5:127. doi:10.1186/1475-2875-5-127.
60. Simpson JA, Aarons L, White NJ. 2001. How can we do pharmacokinetic studies in the tropics? Trans. R. Soc. Trop. Med. Hyg. 95:347-351.
61. Zhao X, Drlica K. 2008. A unified anti-mutant dosing strategy. J. Antimicrob. Chemother. 62:434-436.
62. Read AF, Day T, Huijben S. 2011. The evolution of drug resistance and the curious orthodoxy of aggressive chemotherapy. Proc. Natl. Acad. Sci. U. S. A. 108(Suppl 2):10871-10877.
63. Simpson JA, Agbenyega T, Barnes KI, Di Perri G, Folb P, Gomes M, Krishna S, Krudsood S, Looareesuwan S, Mansor S, McIlleron H, Miller R, Molyneux M, Mwenechanya J, Navaratnam V, Nosten F, Olliaro P, Pang L, Ribeiro I, Tembo M, van Vugt M, Ward S, Weerasuriya K, Win K, White NJ. 2006. Population pharmacokinetics of artesunate and dihydroartemisinin following intra-rectal dosing of artesunate in malaria patients. PLoS Med. 3:e444. doi:10.1371/journal. pmed.0030444.
64. Angus BJ, Thaiaporn I, Chanthapadith K, Suputtamongkol Y, White NJ. 2002. Oral artesunate dose response relationship in acute falciparum malaria. Antimicrob. Agents Chemother. 46:778-782.
65. Krishna S, Planche T, Agbenyega T, Woodrow C, Agranoff D, Bedu- Addo G, Owusu-Ofori AK, Appiah JA, Ramanathan S, Mansor SM, Navaratnam V. 2001. Bioavailability and preliminary clinical efficacy of intrarectal artesunate in Ghanaian children with moderate malaria. Antimicrob. Agents Chemother. 45:509-516.
66. Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, Lwin KM, Ariey F, Hanpithakpong W, Lee SJ, Ringwald P, Silamut K, Imwong M, Chotivanich K, Lim P, Herdman T, An SS, Yeung S, Singhasivanon P, Day NP, Lindegardh N, Socheat D, White NJ. 2009. Artemisinin resistance in Plasmodium falciparum malaria. N. Engl. J. Med. 361:455-467.
67. Carrara VI, Zwang J, Ashley EA, Price RN, Stepniewska K, Barends M, Brockman A, Anderson T, McGready R, Phaiphun L, Proux S, van Vugt M, Hutagalung R, Lwin KM, Phyo AP, Preechapornkul P, Imwong M, Pukrittayakamee S, Singhasivanon P, White NJ, Nosten F. 2009. Changes in the treatment responses to artesunate-mefloquine on the northwestern border of Thailand during 13 years of continuous deployment. PLoS One 4:e4551. doi:10.1371/journal.pone.0004551.
68. Artemether-Quinine Meta-analysis Study Group 2001. A meta-analysis using individual patient data of trials comparing artemether with quinine in the treatment of severe falciparum malaria. Trans. R. Soc. Trop. Med. Hyg. 95:637-650.
69. White NJ, Miller KD, Churchill FC. 1988. Chloroquine treatment of severe malaria in children. Pharmacokinetics, toxicity, and new dosage recommendations. N. Engl. J. Med. 319:1493-1500.
70. Hien TT, Davis TM, Chuong LV, Ilett KF, Sinh DX, Phu NH, Agus C, Chiswell GM, White NJ, Farrar J. 2004. Comparative pharmacokinetics of intramuscular artesunate and artemether in patients with severe falciparum malaria. Antimicrob. Agents Chemother. 48:4234-4239.
71. Murphy SA, Mberu E, Muhia D, English M, Crawley J, Waruiru C, Lowe B, Newton CR, Winstanley P, Marsh K, Watkins WM. 1997. The disposition of intramuscular artemether in children with cerebral malaria; a preliminary study. Trans. R. Soc. Trop. Med. Hyg. 91:331-334.
72. Phu NH, Tuan PQ, Day N, Mai NT, Chau TT, Chuong LV, Sinh DX, White NJ, Farrar J, Hien TT. 2010. Randomized controlled trial of artesunate or artemether in Vietnamese adults with severe falciparum malaria. Malar. J. 9:97. doi:10.1186/1475-2875-9-97.
73. Saralamba S, Pan-Ngum W, Maude RJ, Lee SJ, Tarning J, Lindegardh N, Chotivanich K, Nosten F, Day NP, Socheat D, White NJ, Dondorp AM, White LJ. 2011. Intrahost modeling of artemisinin resistance in Plasmodium falciparum. Proc. Natl. Acad. Sci. U. S. A. 108:397-402.
74. White NJ, Krishna S, Waller D, Craddock C, Kwiatkowski D, Brewster D. 1989. Open comparison of intramuscular chloroquine and quinine in children with severe chloroquine-sensitive falciparum malaria. Lancet ii: 1313-1316.
75. Gwer S, Newton CR, Berkley JA. 2007. Over-diagnosis and co-morbidity of severe malaria in African children: a guide for clinicians. Am. J. Trop. Med. Hyg. 77(Suppl):6-13.
76. Hendriksen IC, Mwanga-Amumpaire J, von Seidlein L, Mtove G, White LJ, Olaosebikan R, Lee SJ, Tshefu AK, Woodrow C, Amos B, Karema C, Saiwaew S, Maitland K, Gomes E, Pan-Ngum W, Gesase S, Silamut K, Reyburn H, Joseph S, Chotivanich K, Fanello CI, Day NP, White NJ, Dondorp AM. 2012. Diagnosing severe falciparum malaria in parasitaemic African children: a prospective evaluation of plasma PfHRP2 measurement. PLoS Med. 9:e1001297. doi:10.1371/journal.pmed. 1001297.
77. Douglas AD, Andrews L, Draper SJ, Bojang K, Milligan P, Gilbert SC, Imoukhuede EB, Hill AV. 2011. Substantially reduced pre-patent parasite multiplication rates are associated with naturally acquired immunity to Plasmodium falciparum. J. Infect. Dis. 203:1337-1340.
78. Rockett RJ, Tozer SJ, Peatey C, Bialasiewicz S, Whiley DM, Nissen MD, Trenholme K, Mc Carthy JS, Sloots TP. 2011. A real-time, quantitative PCR method using hydrolysis probes for the monitoring of Plasmodium falciparum load in experimentally infected human volunteers. Malar. J. 10:48. doi:10.1186/1475- 2875-10-48.
79. Kamau E, Tolbert LS, Kortepeter L, Pratt M, Nyakoe N, Muringo L, Ogutu B, Waitumbi JN, Ockenhouse CF. 2011. Development of a highly sensitive genus-specific quantitative reverse transcriptase real-time PCR assay for detection and quantitation of Plasmodium by amplifying RNA and DNA of the 18S rRNA genes. J. Clin. Microbiol. 49:2946-2953.
80. Andrews L, Andersen RF, Webster D, Dunachie S, Walther RM, Bejon P, Hunt-Cooke A, Bergson G, Sanderson F, Hill AV, Gilbert SC. 2005. Quantitative real-time polymerase chain reaction for malaria diagnosis and its use in malaria vaccine clinical trials. Am. J. Trop. Med. Hyg. 73: 191-198.
81. Imoukhuede EB, Andrews L, Milligan P, Berthoud T, Bojang K, Nwakanma D, Ismaili J, Buckee C, Njie F, Keita S, Sowe M, Lang T, Gilbert SC, Greenwood BM, Hill AV. 2007. Low-level malaria infections detected by a sensitive polymerase chain reaction assay and use of this technique in the evaluation of malaria vaccines in an endemic area. Am. J. Trop. Med. Hyg. 76:486-493.